In order to address the severity of SARS-CoV-2 pandemic, we have produced a humanized monoclonal antibody (7F7) neutralizing SARS-CoV-2, B.1.1.7, B.1.351, B. and B.1.617.2 variants by spike protein immunization, mouse splenic fusion, hybridoma screening, and antibody humanization by CDR grafting. This 7F7 neutralizing antibody is further characterized by receptor-binding inhibition, neutralization, and antibody kinetic assays. The antibody is epitope mapped against spike domain proteins for antigen specificity. The Fc region of the antibody is mutated to minimize antibody-dependent enhancement (ADE) immune response.


Technology_COVID-19-Humanized-Mab.png (509 KB)

Featured Product



* Abnova COVID-19 Humanized Antibody (7F7) Under Patent Filing 2021

For any inquiry, please contact : technicalsupport@abnova.com

For any inquiry, please contact
We have placed cookies on your device to make our website better. If you continue using our website, we assume you agree to it. You can learn more details here .